Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET -amplified gastric cancer

SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and amplification (NCT01657214). SAR125844 was a...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2017-10, Vol.8 (45), p.79546-79555
Main Authors: Shitara, Kohei, Kim, Tae Min, Yokota, Tomoya, Goto, Masahiro, Satoh, Taroh, Ahn, Jin-Hee, Kim, Hyo Song, Assadourian, Sylvie, Gomez, Corinne, Harnois, Marzia, Hamauchi, Satoshi, Kudo, Toshihiro, Doi, Toshihido, Bang, Yung-Jue
Format: Article
Language:English
Subjects:
Clinical Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and amplification (NCT01657214). SAR125844 was administered by intravenous infusion (260-570 mg/m ) on days 1, 8, 15, and 22 of each 28-day cycle. Objectives were to determine the maximum tolerated dose (MTD) and to evaluate SAR125844 safety and pharmacokinetic profile. Antitumor activity was also assessed. Of 38 patients enrolled (median age 64.0 years), 22 had gastric cancer, including 14 with amplification. In the dose-escalation cohort ( = 19; unselected population, including three patients with -amplification [two with gastric cancer and one with lung cancer]), the MTD was not reached, and the recommended dose was established at 570 mg/m . Most frequent treatment-emergent adverse events (AEs) were nausea (36.8%), vomiting (34.2%), decreased appetite (28.9%), and fatigue or asthenia, constipation, and abdominal pains (each 21.1%); none appeared to be dose-dependent. Grade ≥ 3 AEs were observed in 39.5% of patients and considered drug-related in 7.9%. SAR125844 exposure increased slightly more than expected by dose proportionality; dose had no significant effect on clearance. No objective responses were observed in the dose-escalation cohort, with seven patients (three gastric cancer, two colorectal cancer, one breast cancer, and one with cancer of unknown primary origin) having stable disease. Modest antitumor activity was observed at 570 mg/m in the dose-expansion cohort, comprising patients with -amplified tumors ( = 19). Two gastric cancer patients had partial responses, seven patients had stable disease (six gastric cancer and one kidney cancer), and 10 patients had progressive disease. Single-agent SAR125844 administered up to 570 mg/m has acceptable tolerability and modest antitumor activity in patients with -amplified gastric cancer.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.18554